Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07078500Phase 2Recruiting

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT06512688Recruiting

Establishing Reference Ranges for Fat-Soluble Vitamins in Healthy Chinese Adults

Role: collaborator

NCT04397211Not ApplicableActive Not Recruiting

Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease

Role: collaborator

All 3 trials loaded